BSM
Bristol Myers Squibb agrees $13 billion deal to acquire MyoKardia
October 6, 2020Manufacturing and Production BSM, FDA, MyoKardia
Bristol Myers Squibb (BMS) is to purchase MyoKardia for $13 billion to boost its heart disease treatments portfolio. The deal …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
